| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_404ad3939c28be90e799904b88ef1f06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1827f73b393c8bb94b9859afa09e5acd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3ea983512e08b3549f85ac864da6d6e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_51c83a4e9db88e548ef3ed906cf51798 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-10022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-10034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-70 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-104 |
| filingDate |
2008-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2012-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_333306ade3bcae128cc5edca1c8b8d53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f78c608fac4088687f9ca2f7febf4d44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b24606afc9933235810a361038b4680 |
| publicationDate |
2012-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8206950-B2 |
| titleOfInvention |
Fusion antigen used as vaccine and method of making them |
| abstract |
Fusion antigen used as vaccine and method of making them. The method includes: (1) selecting a segment of a virus protein sequence that contains a least one epitope; (2) engineering a DNA fragment encoding the selected segment of the virus protein; (3) inserting the DNA fragment into a Pseudomonas Exotoxin A (PE) vector to obtain a chimeric gene plasmid, and expressing the chimeric gene plasmid in a host cell to obtain the chimeric vaccinal virus antigen. The PE vector contains a PE fragment, which has a binding domain and a translocating domain, and a carboxyl terminal moiety, which includes an endoplasmic reticulum retention sequence. The DNA fragment encoding the selected segment of the virus protein is inserted between the PE fragment and the carboxyl terminal moiety. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11426466-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11324833-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11246915-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11504433-B2 |
| priorityDate |
2003-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |